Phase II study of dasatinib in philadelphia chromosome - Negative acute and chronic myeloid diseases, including systemic mastocytosis

Srdan Verstovsek, Ayalew Tefferi, Jorge Cortes, Susan O'Brien, Guillermo Garcia-Manero, Animesh D Pardanani, Cem Akin, Stefan Faderl, Taghi Manshouri, Deborah Thomas, Hagop Kantarjian

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

Purpose: Molecular characterization of Philadelphia chromosome - negative (Ph-) chronic myeloproliferative disorders, such as systemic mastocytosis (SM), has provided a clear rationale for investigating novel targeted therapies. The tyrosine kinase (TK) inhibitor dasatinib is 325-fold more potent against Bcr-Abl TK than imatinib in vitro, significantly inhibiting wild-type KIT and platelet-derived growth factor receptor βTKs, and is active against cells carrying the mutant KIT-D816V gene. Experimental Design: In this phase 2, open-label study, the efficacy of dasatinib (140 mg/d) was investigated in 67 patients with various Ph- myeloid disorders, including SM (n = 33; 28 KIT-D816V positive). Results: The overall response rate to dasatinib in patients with SM was 33%. Only two patients, one with SM-myelofibrosis and one with SM-chronic eosinophilic leukemia, achieved complete response (elimination of mastocytosis) lasting for 5 and 16 months, respectively. Both patients were negative for KIT-D816V mutation, had low tryptase levels, abnormal WBC counts, and anemia, and had failed prior therapy with erythropoietin. Additional nine SM patients had symptomatic response, lasting 3 to 18+ months. Complete responses were achieved in two other patients (acute myeloid leukemia and hypereosinophilic syndrome). No responses were observed among patients with myelodysplastic syndromes and primary myelofibrosis. The majority of adverse events were grade 1/2. Conclusion: These data show that dasatinib therapy may benefit a selected group of SM patients, primarily by improving their symptoms, but it does not eliminate the disease in the patients with KIT-D816V mutation.

Original languageEnglish (US)
Pages (from-to)3906-3915
Number of pages10
JournalClinical Cancer Research
Volume14
Issue number12
DOIs
StatePublished - Jun 15 2008

Fingerprint

Systemic Mastocytosis
Philadelphia Chromosome
Chronic Disease
Primary Myelofibrosis
bcr-abl Fusion Proteins
Hypereosinophilic Syndrome
Mastocytosis
Dasatinib
Platelet-Derived Growth Factor Receptors
Tryptases
Myeloproliferative Disorders
Mutation
Myelodysplastic Syndromes
Erythropoietin
Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Anemia
Research Design
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II study of dasatinib in philadelphia chromosome - Negative acute and chronic myeloid diseases, including systemic mastocytosis. / Verstovsek, Srdan; Tefferi, Ayalew; Cortes, Jorge; O'Brien, Susan; Garcia-Manero, Guillermo; Pardanani, Animesh D; Akin, Cem; Faderl, Stefan; Manshouri, Taghi; Thomas, Deborah; Kantarjian, Hagop.

In: Clinical Cancer Research, Vol. 14, No. 12, 15.06.2008, p. 3906-3915.

Research output: Contribution to journalArticle

Verstovsek, S, Tefferi, A, Cortes, J, O'Brien, S, Garcia-Manero, G, Pardanani, AD, Akin, C, Faderl, S, Manshouri, T, Thomas, D & Kantarjian, H 2008, 'Phase II study of dasatinib in philadelphia chromosome - Negative acute and chronic myeloid diseases, including systemic mastocytosis', Clinical Cancer Research, vol. 14, no. 12, pp. 3906-3915. https://doi.org/10.1158/1078-0432.CCR-08-0366
Verstovsek, Srdan ; Tefferi, Ayalew ; Cortes, Jorge ; O'Brien, Susan ; Garcia-Manero, Guillermo ; Pardanani, Animesh D ; Akin, Cem ; Faderl, Stefan ; Manshouri, Taghi ; Thomas, Deborah ; Kantarjian, Hagop. / Phase II study of dasatinib in philadelphia chromosome - Negative acute and chronic myeloid diseases, including systemic mastocytosis. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 12. pp. 3906-3915.
@article{a1adac99b91145e3afb2a70ef1944cf3,
title = "Phase II study of dasatinib in philadelphia chromosome - Negative acute and chronic myeloid diseases, including systemic mastocytosis",
abstract = "Purpose: Molecular characterization of Philadelphia chromosome - negative (Ph-) chronic myeloproliferative disorders, such as systemic mastocytosis (SM), has provided a clear rationale for investigating novel targeted therapies. The tyrosine kinase (TK) inhibitor dasatinib is 325-fold more potent against Bcr-Abl TK than imatinib in vitro, significantly inhibiting wild-type KIT and platelet-derived growth factor receptor βTKs, and is active against cells carrying the mutant KIT-D816V gene. Experimental Design: In this phase 2, open-label study, the efficacy of dasatinib (140 mg/d) was investigated in 67 patients with various Ph- myeloid disorders, including SM (n = 33; 28 KIT-D816V positive). Results: The overall response rate to dasatinib in patients with SM was 33{\%}. Only two patients, one with SM-myelofibrosis and one with SM-chronic eosinophilic leukemia, achieved complete response (elimination of mastocytosis) lasting for 5 and 16 months, respectively. Both patients were negative for KIT-D816V mutation, had low tryptase levels, abnormal WBC counts, and anemia, and had failed prior therapy with erythropoietin. Additional nine SM patients had symptomatic response, lasting 3 to 18+ months. Complete responses were achieved in two other patients (acute myeloid leukemia and hypereosinophilic syndrome). No responses were observed among patients with myelodysplastic syndromes and primary myelofibrosis. The majority of adverse events were grade 1/2. Conclusion: These data show that dasatinib therapy may benefit a selected group of SM patients, primarily by improving their symptoms, but it does not eliminate the disease in the patients with KIT-D816V mutation.",
author = "Srdan Verstovsek and Ayalew Tefferi and Jorge Cortes and Susan O'Brien and Guillermo Garcia-Manero and Pardanani, {Animesh D} and Cem Akin and Stefan Faderl and Taghi Manshouri and Deborah Thomas and Hagop Kantarjian",
year = "2008",
month = "6",
day = "15",
doi = "10.1158/1078-0432.CCR-08-0366",
language = "English (US)",
volume = "14",
pages = "3906--3915",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Phase II study of dasatinib in philadelphia chromosome - Negative acute and chronic myeloid diseases, including systemic mastocytosis

AU - Verstovsek, Srdan

AU - Tefferi, Ayalew

AU - Cortes, Jorge

AU - O'Brien, Susan

AU - Garcia-Manero, Guillermo

AU - Pardanani, Animesh D

AU - Akin, Cem

AU - Faderl, Stefan

AU - Manshouri, Taghi

AU - Thomas, Deborah

AU - Kantarjian, Hagop

PY - 2008/6/15

Y1 - 2008/6/15

N2 - Purpose: Molecular characterization of Philadelphia chromosome - negative (Ph-) chronic myeloproliferative disorders, such as systemic mastocytosis (SM), has provided a clear rationale for investigating novel targeted therapies. The tyrosine kinase (TK) inhibitor dasatinib is 325-fold more potent against Bcr-Abl TK than imatinib in vitro, significantly inhibiting wild-type KIT and platelet-derived growth factor receptor βTKs, and is active against cells carrying the mutant KIT-D816V gene. Experimental Design: In this phase 2, open-label study, the efficacy of dasatinib (140 mg/d) was investigated in 67 patients with various Ph- myeloid disorders, including SM (n = 33; 28 KIT-D816V positive). Results: The overall response rate to dasatinib in patients with SM was 33%. Only two patients, one with SM-myelofibrosis and one with SM-chronic eosinophilic leukemia, achieved complete response (elimination of mastocytosis) lasting for 5 and 16 months, respectively. Both patients were negative for KIT-D816V mutation, had low tryptase levels, abnormal WBC counts, and anemia, and had failed prior therapy with erythropoietin. Additional nine SM patients had symptomatic response, lasting 3 to 18+ months. Complete responses were achieved in two other patients (acute myeloid leukemia and hypereosinophilic syndrome). No responses were observed among patients with myelodysplastic syndromes and primary myelofibrosis. The majority of adverse events were grade 1/2. Conclusion: These data show that dasatinib therapy may benefit a selected group of SM patients, primarily by improving their symptoms, but it does not eliminate the disease in the patients with KIT-D816V mutation.

AB - Purpose: Molecular characterization of Philadelphia chromosome - negative (Ph-) chronic myeloproliferative disorders, such as systemic mastocytosis (SM), has provided a clear rationale for investigating novel targeted therapies. The tyrosine kinase (TK) inhibitor dasatinib is 325-fold more potent against Bcr-Abl TK than imatinib in vitro, significantly inhibiting wild-type KIT and platelet-derived growth factor receptor βTKs, and is active against cells carrying the mutant KIT-D816V gene. Experimental Design: In this phase 2, open-label study, the efficacy of dasatinib (140 mg/d) was investigated in 67 patients with various Ph- myeloid disorders, including SM (n = 33; 28 KIT-D816V positive). Results: The overall response rate to dasatinib in patients with SM was 33%. Only two patients, one with SM-myelofibrosis and one with SM-chronic eosinophilic leukemia, achieved complete response (elimination of mastocytosis) lasting for 5 and 16 months, respectively. Both patients were negative for KIT-D816V mutation, had low tryptase levels, abnormal WBC counts, and anemia, and had failed prior therapy with erythropoietin. Additional nine SM patients had symptomatic response, lasting 3 to 18+ months. Complete responses were achieved in two other patients (acute myeloid leukemia and hypereosinophilic syndrome). No responses were observed among patients with myelodysplastic syndromes and primary myelofibrosis. The majority of adverse events were grade 1/2. Conclusion: These data show that dasatinib therapy may benefit a selected group of SM patients, primarily by improving their symptoms, but it does not eliminate the disease in the patients with KIT-D816V mutation.

UR - http://www.scopus.com/inward/record.url?scp=52449085884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52449085884&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-0366

DO - 10.1158/1078-0432.CCR-08-0366

M3 - Article

C2 - 18559612

AN - SCOPUS:52449085884

VL - 14

SP - 3906

EP - 3915

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -